Gain Therapeutics (GANX) Return on Capital Employed (2021 - 2026)
Gain Therapeutics (GANX) posted quarterly Return on Capital Employed of 116.59% for Q1 2026, up 18057.0% year-over-year from N/an in Q1 2025, and up 15.61% quarter-over-quarter from 138.16% in Q4 2025.
Gain Therapeutics (GANX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Gain Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 116.59% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 18057.0% year-over-year to 116.59%; the TTM figure through Mar 2026 stood at 116.59% (up 18057.0% YoY), while the FY2025 annual figure was 132.52%, up 4513.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 116.59%, up from 138.16% in the prior quarter.
- The five-year high for Return on Capital Employed was 42.99% in Q1 2022, with the low at 311.8% in Q2 2025.
- The 5-year median for Return on Capital Employed is 175.83% (2024), against an average of 167.87%.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed sank 15141 bps in 2023, then soared 18057 bps in 2026.
- Gain Therapeutics' Return on Capital Employed stood at 80.49% in 2022, then plunged by 142 bps to 195.14% in 2023, then dropped by 12 bps to 218.04% in 2024, then surged by 37 bps to 138.16% in 2025, then grew by 16 bps to 116.59% in 2026.
- Business Quant data shows GANX's Return on Capital Employed at 116.59% in Q1 2026, 138.16% in Q4 2025, and 282.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -141.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.33% |
| Mar 31, 2026 | -116.59% |
| Dec 31, 2025 | -138.16% |
| Sep 30, 2025 | -282.01% |
| Jun 30, 2025 | -311.80% |
| Mar 31, 2025 | -297.16% |
| Dec 31, 2024 | -218.04% |
| Sep 30, 2024 | -175.83% |
| Jun 30, 2024 | -210.86% |
| Mar 31, 2024 | -184.66% |
| Dec 31, 2023 | -195.14% |
| Sep 30, 2023 | -215.13% |
| Jun 30, 2023 | -156.81% |
| Mar 31, 2023 | -112.32% |
| Dec 31, 2022 | -80.49% |
| Sep 30, 2022 | -63.72% |
| Jun 30, 2022 | -52.05% |
| Mar 31, 2022 | -42.99% |
| Dec 31, 2021 | -36.17% |
| Sep 30, 2021 | -30.29% |